Retatrutide is generating considerable interest in obesity medicine, with many asking why retatrutide might be better than existing treatments. As an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon pathways simultaneously, it represents a potentially more comprehensive metabolic approach than currently licensed options such as semaglutide or tirzepatide. Phase 2 trial data have shown notable weight reduction outcomes alongside improvements in cardiometabolic markers. However, retatrutide does not yet hold MHRA or EMA marketing authorisation, and Phase 3 trials are ongoing. This article explains the science, evidence, and important safety considerations.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, targeting appetite, insulin sensitivity, and energy expenditure — a broader mechanism than currently licensed weight management medicines.

Retatrutide is an investigational medicine currently under clinical development for the treatment of obesity and type 2 diabetes. Unlike some earlier weight management medicines, retatrutide is a triple receptor agonist, meaning it simultaneously activates three distinct hormone receptors in the body:

• GLP-1 (glucagon-like peptide-1) — which reduces appetite and slows gastric emptying

• GIP (glucose-dependent insulinotropic polypeptide) — which primarily enhances glucose-dependent insulin secretion and may also influence fat metabolism

• Glucagon receptor — which may increase energy expenditure; however, glucagon receptor activation can also raise blood glucose levels in some individuals, so its net metabolic effect requires careful interpretation

This triple-action mechanism distinguishes retatrutide from existing licensed treatments such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GLP-1/GIP incretin agonist). By engaging all three pathways simultaneously, retatrutide is designed to produce a more comprehensive metabolic effect — targeting appetite, insulin sensitivity, and energy use at the same time. In clinical trials, retatrutide has been administered as a once-weekly subcutaneous injection, though this detail remains subject to the ongoing development programme.

It is important to note that retatrutide does not currently hold a marketing authorisation (licence) from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for clinical use in the UK. As of mid-2024, Phase 2 data have been published and Phase 3 trials are planned or under way (see ClinicalTrials.gov for current registration details); its full safety and efficacy profile is still being established. Patients should not seek to obtain this medicine outside of regulated clinical trial settings, as doing so carries significant and unpredictable health risks. Any discussion about retatrutide should be understood within the context of emerging research rather than established clinical practice.

Clinical Trial Evidence: What the Research Shows

Phase 2 trial data published in the NEJM (2023) showed approximately 24% mean body weight reduction at the highest dose over 48 weeks, alongside improvements in blood pressure, lipid profiles, and fasting glucose, though Phase 3 results are still awaited.

The most significant clinical data on retatrutide to date come from a Phase 2 randomised controlled trial published in the New England Journal of Medicine (Jastreboff et al., 2023), which evaluated the medicine in adults with obesity (BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity) but without type 2 diabetes. The trial enrolled approximately 338 participants across multiple dose groups over 48 weeks. Participants receiving the highest dose of retatrutide (12 mg weekly) achieved a mean body weight reduction of approximately 24% over 48 weeks.

For context, weight loss outcomes in trials of currently licensed treatments include approximately 15% with semaglutide 2.4 mg (STEP 1 trial, Wilding et al., NEJM 2021) and approximately 20–22% with tirzepatide (SURMOUNT-1 trial, Jastreboff et al., NEJM 2022). However, these cross-trial comparisons must be interpreted with considerable caution: the trials differed in population characteristics, duration, dosing schedules, and primary endpoints. Only direct head-to-head trials can reliably establish whether one treatment is superior to another, and no such trials for retatrutide have yet been completed or published.

In addition to weight reduction, the Phase 2 trial reported improvements in several cardiometabolic markers, including:

• Reductions in waist circumference

• Improvements in blood pressure

• Favourable changes in lipid profiles

• Reductions in fasting glucose and insulin resistance

• Increases in heart rate were also observed, consistent with findings seen with other incretin-based therapies

These findings suggest that retatrutide may offer broader metabolic benefits beyond weight loss alone, which is particularly relevant for patients with obesity-related comorbidities such as type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), or elevated cardiovascular risk.

Phase 2 trials are designed primarily to assess dosing, tolerability, and preliminary efficacy — they are not powered to detect rare adverse events or long-term outcomes. Phase 3 trials are planned or ongoing (see ClinicalTrials.gov for current status), and until their results are published and reviewed by regulatory bodies such as the MHRA and EMA, definitive conclusions about retatrutide's relative merits compared with existing treatments cannot be drawn.

Potential Benefits, Risks, and Side Effects to Consider

Retatrutide shares a side effect profile with other GLP-1-based therapies, including nausea, vomiting, and increased heart rate; serious risks such as pancreatitis, gallbladder disease, and dehydration also require monitoring.

Based on available Phase 2 data, retatrutide appears to offer a promising benefit profile, particularly in terms of the magnitude of weight loss and its potential to address multiple metabolic pathways simultaneously. For patients who have not achieved adequate weight reduction with existing licensed therapies, a triple agonist approach may theoretically offer additional benefit — though this has not yet been confirmed in head-to-head comparative trials.

The side effect profile of retatrutide shares similarities with other GLP-1-based and incretin therapies. The most commonly reported adverse effects in the Phase 2 clinical trial include:

• Nausea and vomiting — particularly during dose escalation

• Diarrhoea and constipation

• Decreased appetite (which contributes to weight loss but may also raise nutritional concerns)

• Injection site reactions

• Increases in resting heart rate — a signal consistent with other medicines in this class

In addition, based on the known class effects of GLP-1-based and incretin therapies (as documented in the Summary of Product Characteristics for licensed comparators such as semaglutide 2.4 mg [Wegovy®] and tirzepatide [Mounjaro®]), the following risks are relevant to consider in the context of retatrutide's development:

• Gallbladder disease (including gallstones and cholecystitis) — a recognised risk with rapid weight loss and GLP-1 receptor agonism

• Pancreatitis — a potential signal requiring monitoring; seek urgent medical attention for severe, persistent abdominal pain with or without vomiting

• Dehydration and acute kidney injury (AKI) — may occur secondary to significant gastrointestinal fluid losses, particularly nausea, vomiting, or diarrhoea

Red-flag symptoms — seek urgent medical attention if you experience:

• Severe or persistent abdominal pain, particularly if radiating to the back

• Right upper quadrant pain, fever, or yellowing of the skin or eyes (possible signs of gallbladder problems)

• Signs of dehydration such as dizziness, reduced urine output, or inability to keep fluids down

Of particular clinical interest is the glucagon receptor agonism component of retatrutide. Whilst glucagon activation may increase energy expenditure, it can also raise blood glucose levels in some individuals — a consideration requiring careful monitoring, especially in patients with diabetes. The net glycaemic effect in the Phase 2 trial appeared favourable overall, but longer-term data are needed.

Retatrutide, like other medicines in this class, is not recommended during pregnancy or breastfeeding. Women of childbearing potential should discuss contraception and pre-conception planning with their clinician before starting any weight management medicine.

As retatrutide does not yet hold a marketing authorisation, there is currently no official guidance from NICE regarding its use. Accessing retatrutide outside of a regulated clinical trial — for example, through unregulated online sources — is not only potentially unlawful but carries serious safety risks, including unknown dosing, contamination, and absence of medical supervision.

If you or a healthcare professional suspects an adverse reaction to any medicine, this should be reported to the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Talking to Your GP About Weight Management Options

UK patients should speak to their GP about licensed weight management options — including semaglutide (Wegovy®) and tirzepatide (Mounjaro®) — as retatrutide remains investigational and is not yet available outside clinical trials.

If you are concerned about your weight or are exploring treatment options, the most appropriate first step is to speak with your GP. In the UK, weight management is approached through a structured, evidence-based framework aligned with NICE guideline CG189 (Obesity: identification, assessment and management) and NICE guideline PH53 (Weight management: lifestyle services for overweight or obese adults). This guidance recommends a stepped approach, beginning with lifestyle interventions — including dietary changes, increased physical activity, and behavioural support — before considering pharmacological or surgical options.

Currently, the licensed weight management medicines available in the UK include:

• Orlistat — available on prescription and in lower doses over the counter

• Semaglutide 2.4 mg (Wegovy®) — a GLP-1 receptor agonist licensed for weight management; recommended by NICE in Technology Appraisal TA875 within defined clinical criteria and specialist weight management services

• Tirzepatide (Mounjaro®) — a dual GLP-1/GIP incretin agonist licensed for weight management; recommended by NICE in Technology Appraisal TA1026 within defined clinical criteria and specialist weight management services

Access to these medicines on the NHS is typically through specialist Tier 3 or Tier 4 weight management services, and local referral criteria apply. Your GP can advise on the referral pathway most appropriate for your circumstances.

When speaking to your GP, it may be helpful to:

• Discuss your full medical history, including any existing conditions such as type 2 diabetes, cardiovascular disease, or gastrointestinal disorders

• Ask about referral pathways to specialist weight management services or NHS Tier 3 obesity clinics

• Raise any concerns about medicines you may have read about online, including investigational medicines such as retatrutide

It is understandable to feel curious — or even hopeful — about emerging treatments that appear to offer greater efficacy. However, patient safety must always come first. Retatrutide may prove to be a significant advance in obesity medicine once full Phase 3 trial data are available and regulatory review is complete, but until that point, decisions about weight management should be guided by your healthcare team using currently licensed, evidence-based options.

Frequently Asked Questions